Because the production and/or use of insulin is impaired in patients with diabetes, insulin is a mainstay of treatment. Type 1 diabetes results from autoimmune destruction of β-cells, usually leading to absolute insulin deficiency. Type 2 diabetes results from the progressive loss of β-cell insulin secretion that is often accompanied by peripheral insulin resistance.
Learning objectives (Pharmacists):
At the completion of this activity, pharmacists will be able to
- Explain the potential roles of recently improved insulins in the management of type 1 and type 2 diabetes
- Compare and contrast of the characteristics of recently-approved forms of insulin.
- Describe strategies to minimize insulin-induced hypoglycemia, including patient education tools.
- Describe strategies that are effective for educating patients who are resistant to taking insulin.
- Evaluate the medication regimen of a patient with diabetes and make treatment recommendations regarding the use of insulin.
Activity type: Knowledge-based
Target Audience: Pharmacists
Learning level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours of CPE credit (0.20 CEUs). The ACPE Universal Activity Numbers for this activity is 0202-0000-17-162-H01-P.
To obtain credit for "Beyond Oral Antidiabetics: Insulin Therapy Options and Combinations" complete the assessment with a grade of 70% or better, evaluation questions, and CLAIM credit. Participants will need to have a valid pharmacist.com username and password to claim credit. After your credit has been claimed, please visit CPE monitor for your transcript.
APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education assessment. Please note that the questions may not appear in the same order as printed and you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.
Initial release date: June 1, 2017
Expiration date: June 1, 2020 - NO CREDIT GRANTED AFTER THIS DATE
"Beyond Oral Antidiabetics: Insulin Therapy Options and Combinations” is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.
Stuart T. Haines, PharmD, BCPS, BCACP, BC-ADM, Professor, University of Mississippi School of Pharmacy
Stuart T. Haines, PharmD, BCPS, BCACP, BC-ADM, and APhA's editorial staff declares no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete APhA staff disclosures, please see the Education and Accreditation Information section at www.pharmacist.com/apha-disclosures.
There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.
Computer and Internet access is required to complete this activity. Please visit our website to view the Technology System Requirements to have a positive learning experience.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-17-162-H01-P||0.2 CEUs||June 01, 2017 - June 01, 2020|